AOL Money & Finance

Options Update: Human Genome options expensive; shares up 215%

Posted Jul 20th 2009 8:00AM by Paul FosterPaul Foster RSS Feed
Filed under: Options

More

Human Genome (NASDAQ: HGSI) is recently trading at $11.07 in pre-open trading, above its close of $3.32. Human Genome Sciences and GlaxoSmithKline (NYSE: GSK) announced that BENLYSTA met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus. HGSI August 2.5 straddle is priced at $2.45, October 2.5 straddle is priced at $2.75, January 2.5 straddle is priced at $3.25 according to Track Data, suggesting large price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Tags: BENLYSTA, GlaxoSmithKline, gsk, hgsi, Human Genome, HumanGenome, inthenews, option impplied volatility, OptionImppliedVolatility

Symbol Lookup
IndexesChangePrice
DJIA+17.4610,023.42
NASDAQ+7.122,112.44
S&P 500+2.671,069.30

Last updated: November 08, 2009: 05:27 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

  • My Portfolio
  • Create a New Portfolio

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines